Kodiak Sciences announces new data from APEX study of KSI-101

Kodiak Sciences (KOD) announced new data from the APEX study of KSI-101 presented at the Retina Society 58th Annual Scientific Meeting in Chicago, Illinois. Dr. Charles Wykoff, MD, PhD, Deputy Chair of Ophthalmology, Blanton Eye Institute, presented continuing data from the three-arm, open-label Phase 1b APEX study of KSI-101 for the treatment of patients with macular edema secondary to inflammation, in which patients experienced a clinically meaningful gain in best-corrected visual acuity and rapid retinal drying from baseline to week 12. Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart. A single dose of KSI-101 resulted in the majority of patients achieving resolution of intra-retinal and sub-retinal fluid and over 90% of patients achieved retinal dryness by Week 8. The Phase 3 PEAK and PINNACLE studies of KSI-101 are actively enrolling, testing the top two dose levels (5 mg and 10 mg) in patients with MESI.